3,5-bis(trifluoromethyl)-N-(3-amino-4-methyl-phenyl)-benzamide | 879507-32-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-bis(trifluoromethyl)-N-(3-amino-4-methyl-phenyl)-benzamide
• 英文别名: N-(3-amino-4-methylphenyl)-3,5-bis(trifluoromethyl)benzamide
• CAS: 879507-32-1
• 化学式: C₁₆H₁₂F₆N₂O
• 分子量: 362.274
• InChiKey: ICUOUTXTFJWFMM-UHFFFAOYSA-N

物化性质

• 沸点：
  336.4±42.0 °C(Predicted)
• 密度：
  1.426±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3,5-bis(trifluoromethyl)-N-(3-amino-4-methyl-phenyl)-benzamide 以62的产率得到3,5-bis(trifluoromethyl)-N-(3-guanidino-4-methyl-phenyl)-benzamide nitrate
  参考文献：
  名称：

  Crystal form of phenylamino pyrimidine derivatives

  摘要：

  本发明涉及(3,5-双三氟甲基)-N-[4-甲基-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯基]-苯甲酰胺（式I）的一种特定结晶形式，其制备方法，含有该结晶形式的制药组合物以及其作为人类抗肿瘤剂的用途。式I化合物，也称为AN-019。

  公开号：

  US08067422B2
• 作为产物：
  描述：

  3,5-bis(trifluoromethyl)-N-(4-methyl-3-nitro-phenyl)-benzamide 在 palladium on carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 3,5-bis(trifluoromethyl)-N-(3-amino-4-methyl-phenyl)-benzamide
  参考文献：
  名称：

  氨基喹唑啉衍生物的合成及其对黑素瘤细胞系的抗增殖活性

  摘要：

  描述了一系列新的氨基喹唑啉衍生物1a – r的合成及其对A375人黑素瘤细胞系的抗增殖活性。其中，有6种化合物显示出比索拉非尼（作为参考化合物）优越的抗增殖活性。尤其是，具有代表性的化合物1q带有chromen-4-one的部分表现出优异的抗增殖活性（IC 50  = 0.006μM）和相对于HS27成纤维细胞系的良好选择性。

  DOI：

  10.1016/j.bmcl.2010.08.010

文献信息

• [EN] NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE<br/>[FR] NOUVEAUX DERIVES DE PHENYLAMINOPYRIMIDINE EN TANT QU'INHIBITEURS DE BCR-ABL KINASE
  申请人：NATCO PHARMA LTD

  公开号：WO2006027795A1

  公开（公告）日：2006-03-16

  The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine derivatives and processes for their preparation. The invention particularly relates to novel Phenyl pyrimidine amine derivatives of the general formula (I). The novel compounds of the formula 1 can be used in the therapy of Chronic Myeloid Leukemia (CML). Since the IC₅₀; 191 values of these molecules are in the range 0.1 to 10.0 nm, these novel compounds are potentially useful for the treatment of CML.

  本发明涉及用于制备新型苯基氨基嘧啶衍生物的中间体，新型苯基氨基嘧啶衍生物。含有新型苯基氨基嘧啶衍生物的药物组合物及其制备方法。本发明特别涉及一般式（I）的新型苯基嘧啶胺衍生物。一般式1的新化合物可用于慢性髓细胞白血病（CML）的治疗。由于这些分子的IC₅₀；191值在0.1至10.0 nm范围内，这些新型化合物有望用于治疗CML。
• CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES
  申请人：Kompella Amala kishan

  公开号：US20090227611A1

  公开（公告）日：2009-09-10

  The present invention relates to a particular form of the (3,5-bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula I), processes for the preparation thereof, pharmaceutical compositions containing this crystal form, and their use as anti tumor agent in humans. The compound of formula I, also known as AN-019, is:

  本发明涉及一种特定形式的（3,5-双三氟甲基）-N-[4-甲基-3-(4-吡啶-3基-嘧啶-2基氨基)-苯基]-苯甲酰胺（化学式 I），其制备方法，含有该晶体形式的药物组合物，以及其作为人类抗肿瘤药物的用途。化学式 I 的化合物，也被称为 AN-019。
• Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38α MAP kinase inhibitors
  作者：Stephen T. Wrobleski、Shuqun Lin、John Hynes、Hong Wu、Sidney Pitt、Ding Ren Shen、Rosemary Zhang、Kathleen M. Gillooly、David J. Shuster、Kim W. McIntyre、Arthur M. Doweyko、Kevin F. Kish、Jeffrey A. Tredup、Gerald J. Duke、John S. Sack、Murray McKinnon、John Dodd、Joel C. Barrish、Gary L. Schieven、Katerina Leftheris

  DOI：10.1016/j.bmcl.2008.02.067

  日期：2008.4

  A novel series of compounds based on the pyrrolo[2,1-f][1,2,4]triazine ring system have been identified as potent p38 alpha MAP kinase inhibitors. The synthesis, structure-activity relationships (SAR), and in vivo activity of selected analogs from this class of inhibitors are reported. Additional studies based on X-ray co-crystallography have revealed that one of the potent inhibitors from this series

  基于吡咯并[2,1-f] [1,2,4]三嗪环系统的一系列新化合物已被鉴定为有效的p38αMAP激酶抑制剂。报道了从这类抑制剂中选择的类似物的合成，结构-活性关系（SAR）和体内活性。基于X射线共晶体的其他研究表明，该系列的有效抑制剂之一与p38α酶的DFG-out构象结合。
• PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE
  申请人：KOMPELLA Amala Kishan

  公开号：US20080306100A1

  公开（公告）日：2008-12-11

  The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine derivatives and processes for their preparation. The invention particularly relates to novel Phenyl pyrimidine amine derivatives of the general formula (I). The novel compounds of the formula 1 can be used in the therapy of Chronic Myeloid Leukemia (CML). Since the IC 50 ; 191 values of these molecules are in the range 0.1 to 10.0 nm, these novel compounds are potentially useful for the treatment of CML. The present invention relates to a particular form of the (3,5-bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula I), processes for the preparation thereof, pharmaceutical compositions containing this crystal form, and their use as anti tumor agent in humans. The compound of formula I, also known as AN-019, is: This invention relates to a process for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula (I)) starting from 4-methyl-2-nitro-aniline (formula (II)) through intermediates (3-trifluoromethylsulfonyl)-N-[4-methyl-3-nitrophenyl]-benzamide (formula (III)), (3-trifluoromethylsulfonyl)-N-[3-amino-4-methylphenyl]-benzamide (formula (IV)) and (3-trifluoromethylsulfonyl)-N-[ 3 -guanidino- 4 -methylphenyl]-benzamide (formula (V)). This invention also relates to processes for the preparation of these intermediates. The compound of formula (I), also known as AN-024, is:

  本发明涉及用于制备新的苯基氨基嘧啶衍生物的新中间体，新的苯基氨基嘧啶衍生物，含有这些新的苯基氨基嘧啶衍生物的制药组合物以及它们的制备过程。本发明特别涉及一般式（I）的新苯基嘧啶胺衍生物。公式1的新化合物可用于慢性髓细胞白血病（CML）的治疗。由于这些分子的IC50; 191值在0.1至10.0纳米的范围内，这些新化合物有潜在的用于治疗CML的作用。本发明涉及一种特定形式的（3,5-双三氟甲基）-N- [4-甲基-3-（4-吡啶-3-基-嘧啶-2-基氨基）-苯基] -苯甲酰胺（公式I），其制备过程，含有该晶体形式的制药组合物，以及它们在人体内作为抗肿瘤剂的用途。公式I的化合物，也称为AN-019，是：本发明涉及一种从4-甲基-2-硝基苯胺（公式（II））通过中间体（3-三氟甲基磺酰基）-N- [4-甲基-3-硝基苯基] -苯甲酰胺（公式（III）），（3-三氟甲基磺酰基）-N- [3-氨基-4-甲基苯基] -苯甲酰胺（公式（IV））和（3-三氟甲基磺酰基）-N- [3-胍基-4-甲基苯基] -苯甲酰胺（公式（V））开始制备（3-三氟甲基磺酰基）-N- [4-甲基-3-（4-吡啶-3-基-嘧啶-2-基氨基）-苯基] -苯甲酰胺（公式（I））的过程。本发明还涉及制备这些中间体的过程。公式（I）的化合物，也称为AN-024，是：
• Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
  申请人：Natco Pharma Limited

  公开号：EP2295424A1

  公开（公告）日：2011-03-16

  The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine derivatives and processes for their preparation. The invention particularly relates to novel Phenyl pyrimidine amine derivatives of the general formula (I), and corresponding intermediates XV.

  本发明涉及用于制备新型苯氨基嘧啶衍生物、新型苯氨基嘧啶衍生物的新型中间体。含有新型苯氨基嘧啶衍生物的药物组合物及其制备工艺。本发明特别涉及通式(I)的新型苯基嘧啶胺衍生物和相应的中间体 XV。